Abstract
The reversible posterior leukoencephalopathy syndrome (RPLES) is a condition characterised by reversible neurological and radiological findings that has been associated with use of immunosuppressive, chemotherapeutic and more recently novel targeted therapies. We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy. The clinical, radiological and EEG findings during and post event are presented and are in keeping with a diagnosis of RPLES. Early recognition of this rare syndrome, supportive management and withdrawal of the offending agent appear to result in a reversal of the manifestations described.
| Original language | English |
|---|---|
| Pages (from-to) | 459-463 |
| Number of pages | 5 |
| Journal | Lung Cancer |
| Volume | 56 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2007 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chemotherapy
- Cisplatin
- Encephalopathy
- Gemcitabine
- Lung malignancy
- Seizures
Fingerprint
Dive into the research topics of 'Chemotherapy induced reversible posterior leukoencephalopathy syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver